United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read General business news Crest Nicholson (LSE: CRST) posts FY25 profit growth as mid-premium strategy begins to take hold Crest Nicholson is narrowing its focus to mid-premium homes. Find out how FY25 results reflect this pivot—and what could define FY26 success. bySrinathJanuary 31, 2026